Kintz Samuel — SEC Form 4 filings
SEC reporting owner CIK 1967168. 30 Form 4 filings on record with FilingPulse; latest filed 2025-11-19.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2024-01-29 to 2025-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 46 legs across 28 filings — 304,842 shares, $6,787,934 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 47,709 shares @ $25.04 ($1,194,700) in Enliven Therapeutics, Inc., filed 2024-04-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | PRESIDENT AND CEO, Director | 30 | — | 46 legs · 304,842 sh · $6,787,934 | 14 |
Form 4 filings — Kintz Samuel
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-11-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $21.82 | EDGAR |
| 2025-10-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $21.33 | EDGAR |
| 2025-09-30 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 3,700 @ $20.06 | EDGAR |
| 2025-09-25 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 2,800 @ $20.03 | EDGAR |
| 2025-09-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $19.09 · Sale (S): 1,000 @ $20.25 | EDGAR |
| 2025-08-21 | 4/A | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,517 @ $20.00 | EDGAR |
| 2025-08-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 10,393 @ $20.02 · Sale (S): 590 @ $20 | EDGAR |
| 2025-07-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,150 @ $21.58 · Sale (S): 4,687 @ $22.69 · Sale (S): 3,663 @ $23.37 | EDGAR |
| 2025-06-18 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 10,502 @ $22.08 · Sale (S): 1,998 @ $22.75 | EDGAR |
| 2025-06-05 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7,500 @ $20.05 | EDGAR |
| 2025-05-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $16.49 | EDGAR |
| 2025-05-05 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,330 @ $20.08 · Sale (S): 2,170 @ $20.00 | EDGAR |
| 2025-04-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $16.42 | EDGAR |
| 2025-03-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $20.83 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 490,000 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 924 @ $30.00 | EDGAR |
| 2024-10-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 13,167 @ $27.95 · Sale (S): 100 @ $28.51 · Sale (S): 13,880 @ $28.07 · Sale (S): 2,830 @ $28.53 | EDGAR |
| 2024-10-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,206 @ $27.51 · Sale (S): 2,730 @ $27.50 | EDGAR |
| 2024-10-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 526 @ $27.54 | EDGAR |
| 2024-08-28 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,000 @ $22.89 | EDGAR |
| 2024-08-02 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 2,270 @ $27.56 | EDGAR |
| 2024-07-29 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 3,793 @ $24.53 · Sale (S): 8,164 @ $25.10 · Sale (S): 43 @ $25.83 | EDGAR |
| 2024-06-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 11,422 @ $21.63 · Sale (S): 578 @ $22.30 | EDGAR |
| 2024-05-30 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 6,681 @ $22.86 · Sale (S): 5,219 @ $23.57 · Sale (S): 100 @ $24.34 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-04-29 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 12,000 @ $16.89 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 47,709 @ $1.12 · Sale (S): 47,709 @ $25.04 · Option exercise (M): 47,709 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 7,329 @ $17.17 · Sale (S): 4,671 @ $18.16 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 7,624 @ $16.69 · Sale (S): 4,376 @ $17.24 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 410,000 (derivative) @ $0 | EDGAR |
| 2024-01-29 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 2,542 @ $14.94 · Sale (S): 9,458 @ $15.89 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1967168 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →